Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy

A. Moghrabi, H. S. Friedman, P. C. Burger, R. Tien, W. J. Oakes

Research output: Contribution to journalArticlepeer-review

Abstract

Six patients with optic pathway gliomas who were previously managed with surgery and/or chemotherapy were treated with carboplatin (560 mg/sq m) after radiographic evidence of disease progression. The median age at diagnosis was 2 years (range 4 months to 7 years), and the interval between diagnosis and carboplatin therapy ranged between 7 months and 6.5 years (median 1.8 years). Treatment was given at 4-week intervals and continued until unacceptable toxicity supervened, the disease progressed, or the disease was stable for 12 months. All patients demonstrated disease stability at the outset of the third cycle and continued to do so at the time of this writing. Two patients are 16 and 32 months from initial carboplatin therapy and have been off treatment for 5 and 14 months, respectively; two patients are still receiving therapy at 7 and 11 months after their initial treatment. During the study, two patients developed hypersensitivity to the drug, requiring its discontinuation. Toxicity was minimal, consisting mainly of thrombocytopenia, requiring a one-dose reduction in four of the six treated patients. No platelet transfusions were needed. These results suggest that carboplatin can arrest growth of progressive optic pathway gliomas in children and can allow delay of radiotherapy. A larger trial will be required to define the optimal use of carboplatin in the treatment of low-grade gliomas in children.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalJournal of neurosurgery
Volume79
Issue number2
DOIs
StatePublished - 1993

Keywords

  • astrocytoma
  • carboplatin
  • chemotherapy
  • children
  • low-grade glioma
  • optic pathway

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy'. Together they form a unique fingerprint.

Cite this